Clinical Trial Update: Pembrolizumab Plus 177Lu-PSMA-617 in Patients With Castration Resistant Prostate Cancer [Phase 2]

View source ↗

Summary

Phase 2 clinical trial evaluating pembrolizumab in combination with 177Lu-PSMA-617 for castration-resistant prostate cancer, including metastatic castration-res…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Castration-resistant Prostate Cancer
• Prostate Cancer

Drugs mentioned

• 177Lu-PSMA-617 (Lutetium-177 PSMA-617)
• Pembrolizumab (pembrolizumab)

Snippet

Sponsor: University of California, San Francisco | Conditions: Castrate Resistant Prostate Cancer, Metastatic Castration-resistant Prostate Cancer | Phase 2 | Status: RECRUITING